Alan S. Cuthbertson
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2023
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Journal: Molecular cancer therapeutics
Published: January 18, 2023
Targeted thorium-227 conjugates as treatment options in oncology.
Journal: Frontiers in medicine
Published: October 15, 2022
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Journal: Frontiers in medicine
Published: August 31, 2022
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Journal: Journal for immunotherapy of cancer
Published: September 06, 2021
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 19, 2021
In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: May 20, 2021
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: April 08, 2020
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 18, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2019
Last Updated: 09/26/2026